Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients

Merck & Co Inc's MRK Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS).
The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.
Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients.
The treatment regime included Keytruda + Chemo combo, then continued as a single agent every six weeks for up to 14 cycles.
At a pre-specified interim analysis review, the regime demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy alone.
The safety profile of Keytruda was consistent with that observed in previously reported studies; no new safety signals were identified.
This trial was sponsored by the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.
Price Action: MRK shares are down 0.63% at $102.81 on the last check Friday.

Momentum20.10

Growth98.20

Quality50.32

Value17.87

Short

Medium

Long